Edoxaban dose, frailty, and outcomes in patients with atrial fibrillation: the ETNA-AF-Europe 4-year follow-up
Sign Up to like & getrecommendations! Published in 2024 at "European Heart Journal"
DOI: 10.1093/eurheartj/ehae666.3134
Abstract: Frailty is a common reason to choose non-recommended (non-rec) doses of non-vitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation (AF); however, it is not known how this practice affects stroke and bleeding outcomes. To assess… read more here.
Keywords: rec; non rec; rec 30mg; frailty ... See more keywords